GH therapy can increase short-term growth and improve ( near ) final height .
Increases in height are such that treated individuals remain relatively short when compared with peers of normal stature .
BACKGROUND Idiopathic short stature ( ISS ) refers to children who are very short compared with their peers for unknown or hereditary reasons .
Recombinant human growth hormone ( GH ) has been used to increase growth and final height in children with ISS .
OBJECTIVES To assess the effects of recombinant human GH on short-term growth and final height in children with ISS .
The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay
We evaluated the effect of six-month treatment with growth hormone ( GH ) or low-dose ox and rolone in a group of boys with constitutional growth delay ( CGD ) . Sixteen boys were r and omly assigned to two treatment groups . Group 1 received GH ( 0.6 U/kg/week sc 5–6 times/week ) and Group 2 received ox and rolone ( 0.07 mg/kg po ) . The boys of the two groups were closely matched for age ( 13.7 ± 0.5 and 12.8 ± 0.4 years ) ( mean ± SE ) , chronologic age/bone age ratio ( 1.15 ± 0.04 and 1.16 ± 0.02 ) , height st and ard deviation score ( SDS ; −2.7 ± 0.4 and −2.5 ± 0.3 ) and pretreatment height velocity ( HV ) ( 3.7 ± 0.8 and 4.0 ± 0.4 cm/year ) . Other known causes of short stature were excluded in all subjects , and none had taken long-term medication prior to the study . After 6 months of treatment HV increased to 7.5 ± 0.4 and to 8.1 ± 0.5 cm/year in group 1 and 2 , respectively . Plasma IGF-I concentrations rose significantly after treatment in both groups . Predicted adult height was not significantly affected by either GH or ox and rolone treatment . We conclude that a short-term course of low-dose ox and rolone is as effective as GH to accelerate growth in boys with CGD . Low-dose ox and rolone represents an effective , cheap , and convenient therapeutic approach in boys with CGD
GH therapy can increase short-term growth and improve ( near ) final height .
Increases in height are such that treated individuals remain relatively short when compared with peers of normal stature .
BACKGROUND Idiopathic short stature ( ISS ) refers to children who are very short compared with their peers for unknown or hereditary reasons .
Recombinant human growth hormone ( GH ) has been used to increase growth and final height in children with ISS .
OBJECTIVES To assess the effects of recombinant human GH on short-term growth and final height in children with ISS .